期刊
ANNALS OF ONCOLOGY
卷 20, 期 12, 页码 2013-2017出版社
OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdp230
关键词
HBV reactivation; lymphoma; occult hepatitis B carrier
类别
资金
- Ministry of Education, Culture, Sports, Science and Technology [19591116]
- Smoking Research Foundation
- Grants-in-Aid for Scientific Research [19591116] Funding Source: KAKEN
Patients and methods: Forty-eight of 127 (37.8%) lymphoma patients were HBsAg negative and HBcAb positive, and 24 of these patients were then given liver function tests and HBsAg tests monthly and serum HBV DNA every 3 months. Results: HBV reactivation was observed in two patients (4.1%) who had received intensive chemotherapy including steroid and rituximab. Immediate administration of entecavir therapy after elevation of HBV DNA level was conducted, and this resulted in reduction of it and improvement of liver function test. Conclusions: Rituximab plus steroid-containing regimens may increase the risk of HBV reactivation in HBsAg-negative and HBcAb-positive lymphoma patients. More ambitious prospective studies are required to establish clinically useful or cost-effective follow-up methods for control of HBV reactivation in lymphoma patients with occult HBV infection.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据